The global Prefilled Syringes Market is on track to grow from USD 7.1 billion in 2024 to USD 13.1 billion by 2030, achieving a CAGR of 10.8%. Prefilled syringes offer a convenient and precise method for administering single doses of medication, reducing drug waste and extending the shelf life of products. The market is driven by the rising incidence of chronic diseases, increased demand for efficient drug delivery systems, and favorable regulatory support for safer injection methods. These syringes are frequently used for biologics, vaccines, and other therapeutic products, enhancing patient safety by reducing errors and improving dosing accuracy. The market is expanding as chronic diseases become more prevalent and self-administration becomes more common. However, challenges such as product recalls and competition from alternative drug delivery methods may pose risks to market growth. The growing demand for biologics and biosimilars is a key driver, with glass and single-chamber syringes expected to dominate. North America leads the market, supported by its advanced healthcare infrastructure and high demand for precise drug delivery solutions. Key players include BD, Gerresheimer AG, SCHOTT, and West Pharmaceutical Services.
Prefilled Syringes Market Dynamics
Drivers
· Rising target disease population
· Rapid growth in generic products
· Rising adoption of self-medication and digitalization
· Affordable cost with increased efficiency of prefilled syringes
· Technological advancements
Restraints
· Dearth of prefilled syringes with integrated safety features
Opportunities
· Growing healthcare infrastructure across emerging markets
· Surge of biologics and biosimilars in biopharma industry
· Increasing adoption of wearable drug delivery technologies
Challenges
· Availability of cheaper alternatives
· Challenges associated with manufacturing of prefilled syringes
Key Market Players
Becton, Dickinson and Company (US), Gerresheimer (Germany), SCHOTT AG (Germany), West Pharmaceutical Services, Inc. (US), Baxter International Inc (US), Ompi (Italy), Catalent, Inc. (US), Weigao Group (China), Vetter Pharma International GmbH (Germany), Nipro Corporation (Japan), Elcam Medical (Israel), YPSOMED (Switzerland), Oval Medical Technologies (UK), SHL Medical AG (Switzerland), Terumo (Japan).
North America accounted for the largest market share of the global prefilled syringes industry, by region in the forecast period.The pre-filled syringe market is anticipated to be dominated by the North American region due to a number of factors, including an advanced healthcare infrastructure, a high prevalence of chronic diseases, and a focus on patient safety and technological innovation. Its dominant position in the market is also a result of the region’s well-established pharmaceutical industry and rising demand for practical and precise drug delivery solutions. Furthermore, continued R&D expenditures and favorable regulatory environments in North America contribute to the expansion and use of pre-filled syringes.
Recent Developments
· In October 2018, Becton, Dickinson and Company launched the BD Intevi 1mL two-step disposable autoinjector.
· In July 2020, Becton, Dickinson and Company entered into an partnership with Biomedical Advanced Research and Development Authority (BARDA) (US)
· In July 2018, Becton, Dickinson and Company acquired Teva Medical Inc. (US)
Content Source:
Comments